A Phase I Trial of ZIO-101 in Hematologic Cancers

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical. You must be diagnosed to have relapsed/refractory leukemia or lymphoma (blood cancer) and have tried other standard therapies.

This study is designed to determine whether ZIO-101 may be given safely. The study will also test whether ZIO-101 helps to treat blood cancer.

We anticipate that approximately 22 to 35 patients will take part in this study.

Arsenic has been used as a medicinal agent for centuries in many different cultures. Most recently in the United States, an inorganic arsenic compound was approved by the FDA for the treatment of patients with relapsed acute promyelocytic leukemia (APL). However, use of inorganic arsenic is limited by a narrow range of activity and systemic toxicity, most notably of the cardiac system.

ZIO-101 is an organic arsenic derivative. In vitro testing in both the National Cancer Institute (NCI) cancer cell panel and in vivo testing in a leukemia animal model demonstrated substantial activity of SGLU against hematologic cancers. In vitro testing of SGLU using the NCI human cancer cell panel also detected activity against lung, colon and brain cancers, melanoma, and ovary and kidney cancers. Moderate activity was seen against breast and prostate cancers cells. Data suggest that organic arsenic generates reactive oxygen species in the cells to induce apoptosis and cell cycle arrest.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziopharm

Criteria

Inclusion Criteria:

• Subjects must have relapsed/refractory leukemia or lymphoma for which no standard therapies are anticipated to result in a durable remission. Relapsed/refractory leukemia/lymphoma includes acute leukemia, chronic myeloproliferative disease, chronic lymphoproliferative disease, multiple myeloma, and any type of lymphoma. Subjects with poor-risk myelodysplasia (MDS) are also candidates for this protocol. Poor risk MDS includes refractory anemia with excess blasts or excess blasts in transformation, and chronic myelomonocytic leukemia.

• ECOG performance status of ≤ 2.

• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. Nursing subjects are excluded. Sexually active men must also use acceptable contraceptive methods. Pregnant and nursing subjects are excluded because the effects of ZIO-101 on a fetus or nursing child are unknown.

• Must be able and willing to give written informed consent.

• Absent rapidly progressing disease, the interval from cancer therapy should be ≥ 3 weeks. Subjects receiving hydroxyurea should be on stable dose ≥ 7 days before beginning treatment protocol. Persisting chronic toxicities from prior therapy must be ≤ grade 1.

• Subjects must have the following clinical laboratory values:

• Serum creatinine ≤ 2 x the upper limit of normal

• Total bilirubin ≤ 2 x the upper limit of normal.

• Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) ≤ 3 x the upper limit of normal.

• QTc interval < 450-470 mSec

Exclusion Criteria:

Subjects with any one of the following criteria will not be eligible for study participation:

• Patients with indolent and stable myeloma, MDS or CLL not requiring therapy are not eligible.

• Central nervous system (CNS) involvement with cancer.

• Uncontrolled active infection of any kind. Subjects with infections that are under active treatment with antibiotics and whose infections are controlled may be entered to the study.

• Active heart disease including myocardial infarction within previous 6 months; symptomatic coronary artery disease; any type of chronic, ongoing arrhythmias; or uncontrolled congestive heart failure.

• Concomitant therapy for hematologic cancer (except hydroxyurea).

• NYHA functional class ≥ 3, myocardial infarction ≤ 6 mo or uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; QTc ≥450msec; AV-block ≥ grade-2 or Left Bundle Branch Block.